Highlights Agenus Inc.

Equities

AGEN

US00847G8042

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-03 pm EDT			5-day change	1st Jan Change
13.07 ^USD	+4.39%		+11.80%	-21.07%

Apr. 12	Sector Update: Health Care Stocks Slipping Late Afternoon	MT
Apr. 12	Sector Update: Health Care	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Slipping Late Afternoon	Apr. 12	MT
Sector Update: Health Care	Apr. 12	MT
Agenus Shares Decline After Update on Early Stage Colorectal Cancer Drug Trial	Apr. 12	MT
Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer	Apr. 12	CI
Reverse Split: 1 of 20	Apr. 11	FA
Agenus Stockholders Approve 1-for-20 Reverse Stock Split	Apr. 05	MT
Earnings Flash (AGEN) AGENUS Posts Q4 Revenue $83.8M	Mar. 14	MT
Agenus Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Agenus Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
Agenus Inc. Announces Preclinical Data on BMS-986442 at AACR 2024	Mar. 06	CI
Ginkgo Bioworks, Agenus Unit Win Contract to Discover, Develop Vaccine Adjuvants	Feb. 15	MT
Agenus Inc. Announces Data from an Investigator Sponsored Trial Evaluating Botensilimab in Combination with Balstilimab in Neoadjuvant Colorectal Cancer	Dec. 20	CI
Earnings Flash (AGEN) AGENUS Posts Q3 Revenue $24.3M	Nov. 07	MT
Agenus Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Agenus Inc. Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and Sarcoma	23-10-22	CI
Agenus Inc. Announces Expanded Data from the Company's Phase 1B Study of Botensilimab in Combination with Balstilimab (Bal, Anti-Pd-1) in Patients with Advanced Sarcomas	23-10-21	CI
Agenus Inc. Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal Cancer	23-10-10	CI
Agenus Inc. Prioritizes Resources to Accelerate Registration and Commercialization of BOT/BAL Program in Multiple Cancers	23-08-23	CI
Earnings Flash (AGEN) AGENUS Reports Q2 Revenue $25.3M, vs. Street Est of $24.1M	23-08-08	MT
Agenus Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Agenus Inc.

Equities

AGEN

US00847G8042

Highlights

Filters